Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment
Beckers, N.G.M.; Macklon, N.S.; Eijkemans, M.J.; Ludwig, M.; Felberbaum, R.E.; Diedrich, K.; Bustion, S.; Loumaye, E.; Fauser, B.C.J.M.
Journal of Clinical Endocrinology and Metabolism 88(9): 4186-4192
2003
ISSN/ISBN: 0021-972X
PMID: 12970285
DOI: 10.1210/jc.2002-021953
Accession: 011067838
Replacing GnRH agonist cotreatment for the prevention of a premature rise in LH during ovarian stimulation for in vitro fertilization (IVF) by the late follicular phase administration of GnRH antagonist may render supplementation of the luteal phase redundant, because of the known rapid recovery of pituitary function after antagonist cessation.
PDF emailed within 0-6 h: $19.90
Related References
Hohmann, F.P.; Macklon, N.S.; Fauser, B.C.J.M. 2003: A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol Journal of Clinical Endocrinology and Metabolism 88(1): 166-173Broekmans, F.J.; Weima, S.M.; te Velde, E.R. 2003: A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol Journal of Clinical Endocrinology and Metabolism 88(9): 4510; author reply 4510-1
Fatemi, H.M.; Polyzos, N.P.; van Vaerenbergh, I.; Bourgain, C.; Blockeel, C.; Alsbjerg, B.; Papanikolaou, E.G.; Humaidan, P. 2013: Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles Fertility and Sterility 100(3): 742-747
Cavagna, M.; Maldonado, L.Guilherme.Louzada.; de Souza Bonetti, T.Carvalho.; de Almeida Ferreira Braga, D.Paes.; Iaconelli, A.; Borges, E. 2010: Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression Fertility and sterility 94(1): 167-172
Kim, C.-H.; Ahn, J.-W.; You, R.-M.; Kim, S.-H.; Chae, H.-D.; Kang, B.-M. 2014: Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization Journal of Reproductive Medicine 59(1-2): 63-68
Kim, C.-H.; Kim, S.-R.; Cheon, Y.-P.; Kim, S.-H.; Chae, H.-D.; Kang, B.-M. 2009: Minimal stimulation using gonadotropin-releasing hormone (GnRH) antagonist and recombinant human follicle-stimulating hormone versus GnRH antagonist multiple-dose protocol in low responders undergoing in vitro fertilization/intracytoplasmic sperm injection Fertility and Sterility 92(6): 2082-2084
Földesi, I.; Brekwoldt, M.; Neulen, J. 2000: Gonadotropin stimulation of progesterone production of granulosa cells derived from in vitro fertilization procedures: comparison of the in vitro biopotency of recombinant follicle stimulating hormone, recombinant luteinizing hormone nad recombinant human chorionic gonadotropin Acta Pharmaceutica Hungarica 70(1): 3-10
Fornaro, F.; Cobellis, L.; Mele, D.; Tassou, A.ò; Badolati, B.; Sorrentino, S.; De Lucia, D.; Colacurci, N. 2007: Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant follicle-stimulating hormone on follicular fluid levels of adhesion molecules during in vitro fertilization Fertility and Sterility 87(1): 39-47
Kolibianakis, E.; Bourgain, C.; Albano, C.; Osmanagaoglu, K.; Smitz, J.; Van Steirteghem, A.; Devroey, P. 2002: Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up Fertility and Sterility 78(5): 1025-1029
Filippo Ubaldi, M.D.; ; Michel Camus, M.D.; ; Johan Smitz, M.D.; Ph.D.; ; Herjan, J.T Coelingh Bennink, M.D.; Ph.D.; ; André Van Steirteghem, M.D.; Ph.D.; ; Paul Devroey, M.D.; Ph.D. 1998: Premature Luteinization in In Vitro Fertilization Cycles Using Gonadotropin-Releasing Hormone Agonist (GnRH-a) and Recombinant Follicle-Stimulating Hormone (FSH) and GnRH-a and Urinary FSH Fertility and Sterility 69(2-Supp-S1): 28-33
Ubaldi, F.; Camus, M.; Smitz, J.; Bennink, H.C.; Van Steirteghem, A.; Devroey, P. 1996: Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH Fertility and Sterility 66(2): 275-280
Barmat, L.I.; Chantilis, S.J.; Hurst, B.S.; Dickey, R.P. 2005: A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization Fertility and Sterility 83(2): 321-330
Barmat, L.I.; Chantilis, S.J.; Hurst, B.S.; Dickey, R.P. 2005: A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/ recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization Fertil. Steril 83(2): 321-330
Ramachandran, A.; Jamdade, K.; Kumar, P.; Adiga, S.K.; Bhat, R.G.; Ferrao, S.R. 2014: Is there a Need for Luteinizing Hormone (LH) Estimation in Patients Undergoing Ovarian Stimulation with Gonadotropin-Releasing Hormone (GnRH) Antagonists and Recombinant Follicle-Stimulating Hormone (rFSH)? Journal of Clinical and Diagnostic Research: Jcdr 8(1): 90-92
Vuong, T.N.L.; Phung, H.T.; Ho, M.T. 2015: Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial Human Reproduction 30(5): 1188-1195
Kyrou, D.; Kolibianakis, E.M.; Fatemi, H.M.; Tarlatzis, B.C.; Tournaye, H.; Devroey, P. 2011: Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial Fertility and Sterility 96(5): 1112-1115
Engmann, L.; DiLuigi, A.; Schmidt, D.; Nulsen, J.; Maier, D.; Benadiva, C. 2008: The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study Fertility and Sterility 89(1): 84-91
De Placido, G.; Mollo, A.; Clarizia, R.; Strina, I.; Conforti, S.; Alviggi, C. 2006: Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response Fertility and Sterility 85(1): 247-250
Ubaldi, F.; Camus, M.; Smitz, J.; Bennink, H.J.T.C.; Van Steirteghem, A.; Devroey, P. 1998: Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRD-a and urinary FSH Fertility and Sterility 69(2): 28S-33S
Miyake, Y.I.; Hirata, T.I.; Osawa, T.; Watanabe, G.; Taya, K. 2000: Changes in peripheral follicle stimulating hormone (FSH), luteinizing hormone (LH), inhibin, estradiol-17 beta , progesterone and testosterone levels before and after the administration of equine chorionic gonadotropin (eCG), human chorionic gonadotropin (hCG) and gonadotropin releasing hormone analogue (GnRH-A) in three cases of bovine gonadal hypoplasia (XY female) Journal of Reproduction and Development 46(6): 381-386